Disc Medicine is laying off about 20% of its workforce after the Food and Drug Administration denied its application for accelerated approval of its bitopertin treatment.
This study suggests is that clinicians "may be able to offer patients a path to meaningful relief in less than 1 week." ...
In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...
Some types of “forever chemicals” are aging men in their 50s and early 60s faster than at other times of life, a new study ...
Those “healthy” alternatives might come with a not-so-sweet catch.
The approval comes under the National Priority Voucher Program, joining Augmentin XR as one of the few approvals from the voucher program as of February 27, 2026. Hernexeos was granted a national ...
Bird populations are declining across North America, with the pace of loss accelerating in heavily farmed regions such as the Midwest.
Rare disease is a major – and growing – area of clinical research and drug development. Of the FDA’s 46 novel drug approvals ...
Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 prelimi ...
The new transcranial magnetic stimulation (TMS) format can shorten the course of depression treatment from six to eight weeks to five days. This was reported on February 25 by Science Daily ...
Discover how white matter changes in the brain can predict aging trajectories and cognitive decline in individuals.
Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results